tbuckley/cabot-search huggingface dataset:
1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011
Authors: Y. Loriot, T. Csoszi, N. Matsubara, S.J. Shin, S.H. Park, V. Atduev, M. Gumus, B.B. Karaca, P. Grivas, R. De Wit, A.O. Siefker-Radtke, D.E. Castellano Gauna, P.H. O'Donnell, T.B. Powles, J. Vuky, Y. Zhao, K. O'hara, S. Franco, B. Homet Moreno, J. Zolnierek
Journal: Annals of Oncology (2022)
1387P Final analysis of the phase Ib/II study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent
Authors: M.C. Markowski, M. Eisenberger, C. Pieczonka, D. Rodriguez, K.G. Barnette, R.H. Getzenberg, M.S. Steiner, D.R. Saltzstein, E.S. Antonarakis, R.F. Tutrone
Journal: Annals of Oncology (2022)
1613P Prevalence and predictive value for 6-month mortality of four criteria for assessment of sarcopenia in older patients with cancer: NutriAgeCancer national prospective cohort study
Authors: C. Martinez-Tapia, K. Rougette, V. Fossey-Diaz, T. Cudennec, C. Taleb, B. Beauplet, L. Balardy, C. Mertens, N. Mitha, M. Bringuier, E. Cotto, S. Estivin, V. Quipourt, F. Canouï-Poitrine, C. Baldini, E. Paillaud
Journal: Annals of Oncology (2022)
1739P Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)
Authors: A.J. Weickhardt, F. Foroudi, J. Xie, K. Kanojia, M. Sidhom, A. Pal, P. Grimison, A. Zhang, S. Ng, C. Tang, E. Hovey, C. Chen, G. Hruby, A. Guminski, M. Mcjannett, C.J. Conduit, N. Lawrentschuk, B. Tran, I.D. Davis, D. Hayne
Journal: Annals of Oncology (2022)
1520P Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study
Authors: H. Salm, M. Eichler, L. Hentschel, S. Richter, P. Hohenberger, B. Kasper, D. Andreou, D. Pink, L. Mütze, K. Arndt, M. Bornhaeuser, J. Schmitt, M.K. Schuler
Journal: Annals of Oncology (2022)
1392P Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes
Authors: K. Rahbar, M. Essler, M. Eiber, C. la Fougère, V. Prasad, W.P. Fendler, P. Rassek, E. Hasa, H. Dittmann, R.A. Bundschuh, K.M. Pabst, M. Kurtinecz, A. Schmall, F. Verholen, O. Sartor
Journal: Annals of Oncology (2022)
1470P Transcriptomic signature and immune infiltrate in metastatic collecting duct renal cell carcinoma patients treated with first-line cabozantinib: Results of exploratory endpoints from BONSAI trial (Meeturo 2)
Authors: E. Verzoni, K. Todoerti, L. Rivoltini, V. Huber, M. Rodolfo, L. Agnelli, A. Devecchi, A. Busico, F. Perrone, G. Centonze, L. De Cecco, M. Claps, V. Guadalupi, M. Stellato, P. Giannatempo, F.G.M. De Braud, G. Procopio, P. Sepe
Journal: Annals of Oncology (2022)
1689P OATD-02 validates the benefits of pharmacological inhibition of arginase 1 and 2 in cancer
Authors: M.M. Grzybowski, R. Blaszczyk, P. Pomper, P.S. Stanczak, B. Borek, A. Gzik, J. Nowicka, K. Jędrzejczak, T. Rejczak, M. Mlącki, N.C. Guner-Chalimoniuk, A. Kikulska, J. Olczak, J. Pęczkowicz-Szyszka, K. Dzwonek, P. Dobrzanski, A. Gołębiowski, Z. Zasłona
Journal: Annals of Oncology (2022)
1611P Clinical determinants of SARS-CoV-2 vaccine response in adults with cancer
Authors: E. Segelov, A. Body, L. Lal, H. Abdulla, S. Turville, Z. Naing, S. Opat, M. Leahy, J.R. Balendra, N. Hamad, R. Mccuaig, S. Rao, K. Lineburg, C. Smith, C.R. MacIntyre, V. Milch, L. Busija, E.S. Ahern
Journal: Annals of Oncology (2022)
1664MO Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients
Authors: E.Y. Zhao, E. Sanz Garcia, Z. Liu, K. Marsh, A. Abdul Razak, A. Spreafico, P.L. Bedard, A.R. Hansen, S. Lheureux, D. Torti, B. Lam, T.J. Pugh, L.L. Siu
Journal: Annals of Oncology (2022)
1672P Tumor and immune cell dynamics at single-cell resolution on combined PARP inhibition and anti-PD-L1 therapy
Authors: J. Vibert, C. Henon, P. Martin Romano, L. Tselikas, L. Colmet-Daage, R. Chabanon, N. Dorvault, A. Gazzah, F. Bouquet, N. Droin, K. Fizazi, D. Vasseur, E. Rouleau, S. Postel-Vinay
Journal: Annals of Oncology (2022)
1485O Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study
Authors: J. Smadja, V. Servois, G. Pierron, S. El Zein, E. Laas, T. Ramtohul, D. Tzanis, S. Watson, S. Bonvalot
Journal: Annals of Oncology (2022)
1450MO Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC
Authors: M-O. Grimm, E. Esteban Gonzalez, P. Barthelemy, M. Schmidinger, J. Busch, B. Perez Valderrama, N. Charnley, M. Schmitz, U. Schumacher, G. Baretton, I. Duran Martinez, G.A. De Velasco Oria, F. Priou, J.P. Maroto Rey, L. Albiges
Journal: Annals of Oncology (2022)
1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
Authors: P. Barthelemy, C. Thibault, E. Voog, J-C. Eymard, A. Ravaud, A. Flechon, C. Abraham Jaillon, W. Hilgers, S. Le Moulec, M. Chasseray, D. Pouessel, Y.E. Amela, V. Lorgis, E. Nicolas, E. Kazan, G. Denechere, M-N. Solbes, P. Lambert, Y. Loriot
Journal: Annals of Oncology (2022)
1538P Prognostic impact of leptin (LEP)-mediated meta-inflammation (MI) in patients (pts) receiving maintenance immunotherapy (IT) for extensive-stage small cell lung cancer (ES-SCLC)
Authors: E. Vita, A. Stefani, G. Piro, I. Sparagna, F. Monaca, M. Di Salvatore, M.G. Ferrara, D. Barone, E. D'Argento, C. Carbone, G. Tortora, E. Bria
Journal: Annals of Oncology (2022)
1740P Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART): An open-label, single-arm, multicenter, phase II trial
Authors: Y. Nagumo, T. Kimura, H. Ishikawa, Y. Sekino, K. Maruo, B.J. Mathis, M. Takemura, Y. Kageyama, H. Ushijima, T. Kawai, H. Yamashita, H. Azuma, T. Naiki, Y. Kobayashi, J. Inokuchi, T. Osawa, Y. Kita, T. Tsuzuki, K. Hashimoto, H. Nishiyama
Journal: Annals of Oncology (2022)
1551O Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study
Authors: R. Kabirian, J. Havas, M.A. Franzoi, C. Coutant, O. Tredan, C. Levy, P.H. Cottu, A. Dhaini Merimeche, S. Guillermet, J-M. Ferrero, S. Giacchetti, T. Petit, F. Dalenc, P. Rouanet, O. Querel, A-L. Martin, B. Pistilli, M. Lambertini, I.V. Luis, A. Di Meglio
Journal: Annals of Oncology (2022)
1550TiP Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)
Authors: L. Paz-Ares, M.L. Johnson, N. Girard, C.L. Hann, M-J. Ahn, M. Nishio, J. Godard, A. Laadem, N. Yoshizuka, M. Qian, B. Cheng, C.M. Rudin
Journal: Annals of Oncology (2022)
1561P Changes of muscle mass, muscle strength and fatigue symptom scale during three cycles of chemotherapy in adult women breast cancer
Authors: A. Kurniawan, N. Sutandyo, S.S. Panigoro, R.D. Hatma, R. Sumantri, A. Adisasmita, D.S. Rivami, S. Budianto
Journal: Annals of Oncology (2022)
1506P Role of 18F-FDG PET/CT in the initial staging of very high risk Ewing sarcoma in a prospective multicentric phase II study: Is there still a place for bone marrow sampling?
Authors: N. Jehanno, N. Corradini, N. Gaspar, C.M. Chevreau, J-C. Gentet, C. Lervat, S. Taque, N. Entz-Werle, L. Mansuy, D. Plantaz, M. Rios, L. Saumet, C. Verite, M-P. Castex, E. Thebaud, T. Cassou-Mounat, V. Mosseri, M. Brahmi, C. Cordero, V. Laurence
Journal: Annals of Oncology (2022)
1456P Long-term survivorship rates for first-line intermediate or poor (I/P) risk advanced renal cell carcinoma (aRCC) patients achieving objective response (OR) with nivolumab plus ipilimumab (N+I)
Authors: S. George, M. Hunger, O. Hughes, J.R. May, M. Dyer, F. Ejzykowicz, M. Kurt
Journal: Annals of Oncology (2022)
1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial
Authors: E. Colomba, L. Carril Ajuria, C. Dalban, L. Derosa, C. Alves Costa Silva, E. Rassy, S. Negrier, C.M. Chevreau, G. Gravis Mescam, S. Oudard, B. Laguerre, P. Barthelemy, M. Gross Goupil, L. Geoffrois, A. Thiery-Vuillemin, F. Joly Lobbedez, S. Ladoire, F. Tantot, B. Escudier, L. Albiges
Journal: Annals of Oncology (2022)
1430P Psychological status and patient perception during the SARS-CoV-2 vaccination campaign in active oncological patients (pts)
Authors: T. Daniela, A. Avancini, L. Belluomini, I. Trestini, S. Zuliani, T. Sava, C. Gaiani, A. Caldart, M. Casali, L. Benini, F. Zacchi, E. Trevisani, F. Bianchi, S.T. Riva, None L. del piccolo, A. Tfaily, M. Rimondini, G. Verlato, S. Pilotto, M. Milella
Journal: Annals of Oncology (2022)
1606P Health care literacy impact on Portuguese cancer patients’ perceived information
Authors: B.F. Lima, J. Barbosa-Martins, A.R. Barbosa, J.C. Mendonca, A.S. Rolo dos Santos, L.C. Oliveira, C. Carvalho, I. Faustino, A. Teixeira, C. Coutinho
Journal: Annals of Oncology (2022)
1445P Family dynamics of pediatric oncology patients in a level III clinic in the city of Cali
Authors: V. Santa Ovalles, L.V. Agudelo Campiño, M.J. Guerrero, A. Botero Carvajal, A.M. Jimenez Urrego, A.C. Guerrero Benitez
Journal: Annals of Oncology (2022)
1486MO The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1 receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor
Authors: H. Gelderblom, M. Huang, M. van de Sande, T. Scharschmidt, O. Kostogryz, L. Alani, T. Huang, L. Hsu, K. Johnson
Journal: Annals of Oncology (2022)
1771P Genomic characteristics and clinical outcomes of HRAS-mutated urothelial bladder cancer
Authors: J.A. Ocejo Gallegos, E. Rodriguez, A. Trabolsi, S. Kareff, J. Yin, P. Walker, W. El-Deiry, B.A. Carneiro, C. Nabhan, G. Lopes, J. Merchan
Journal: Annals of Oncology (2022)
1455P Characterization of patients with metastatic renal cell carcinoma achieving complete response to first-line therapies: Results from the international metastatic renal cell carcinoma database consortium (IMDC)
Authors: K. Takemura, V. Navani, M.S. Ernst, J.C. Wells, T.K. Choueiri, L. Meza, S.K. Pal, J-L. Lee, H. Li, N. Agarwal, A.S. Alva, A.R. Hansen, N.S. Basappa, B.E. Szabados, T.B. Powles, B. Tran, C.M. Hocking, B. Beuselinck, T. Yuasa, D.Y.C. Heng
Journal: Annals of Oncology (2022)
1490MO CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
Authors: M-V. Teleanu, C.E. Heilig, R.W. Hamacher, S. Bauer, R. Mayer-Steinacker, V.I. Gaidzik, P. Horak, L-M. Lanz, T. Muskatewitz, H. Süsse, A. Freitag, M. von Hornung, L. Wacker, C. Von Kalle, T. Barth, S. Fröhling, R.F. Schlenk
Journal: Annals of Oncology (2022)
1744P Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study
Authors: H. Li, M. Chen, C. Xue, L. Li, A. Hu, W. Yang, Z. Zheng, M. Ni, L. Zhang, Y. Zeng, J. Peng, K. Yao, F. Zhou, Z. Liu, X. An, Y. Shi
Journal: Annals of Oncology (2022)
1534P Phase II study of berzosertib + topotecan in patients with relapsed platinum (Pt)-resistant SCLC (DDRiver SCLC 250): Japanese safety run-in
Authors: T. Yoshida, Y. Fujisaka, T. Kurata, N. Yamamoto, A. Thomas, B. Sarholz, R. Hallwachs, J. Bolleddula, T. Kuronita, C. Moulin Correa, L. Paz-Ares
Journal: Annals of Oncology (2022)
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study
Authors: S.E. Rebuzzi, P. Rescigno, A. Signori, M. Brunelli, F. Galuppini, V.G. Vellone, G. Gaggero, M. Maruzzo, M. Milella, F. Vignani, A. Cavo, U. Basso, F. Catalano, V. Murianni, M. Cremante, A. Damassi, M.A. Llaja Obispo, G.L. Banna, S. Buti, G. Fornarini
Journal: Annals of Oncology (2022)
1727P Trametinib enhances PD-L1 expression in KRAS-mutant NSCLC via Id1 downregulation
Authors: A. Puyalto, M. Rodríguez-Remírez, I. López, M. Olmedo López-frías, A. Vilalta, C. Welch, S. Vicent, A. Calvo, I. Gil Bazo
Journal: Annals of Oncology (2022)
1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era
Authors: J. Thouvenin, O. Alhalabi, M. Carlo, L. Carril Ajuria, Z. Bakouny, N. Martinez Chanza, S. Negrier, L. Campedel, M.A. Bilen, D. Borchiellini, J. Chahoud, Y-A. Vano, M. Lodi, P. Barthelemy, S.R. Viswanathan, P. Msaouel, T.K. Choueiri, L. Albiges, N. Tannir, G. Malouf
Journal: Annals of Oncology (2022)
1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit
Authors: J.S. de Bono, E. Castro Marcos, D.A. Laird, K. Fizazi, T. Dorff, S. Zhao, I.M. van Oort, D. Gasparro, F. Calabrò, S. Pignata, L. Geczi, P. Barthelemy, D. Kilari, J.F. Hopkins, H-C. Chen, C.G. Healy, J. Chelliserry, G.V. Scagliotti, N. Mehra
Journal: Annals of Oncology (2022)
1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients
Authors: K. Fizazi, A. Bernard-Tessier, P. Barthelemy, T. Utriainen, G. Roubaud, A. Flechon, J.C.M. van der Voet, G. Gravis Mescam, R. Ratta, R.H. Jones, O.A. Parikh, M.M.E. Tanner, C. Garratt, L. Nevalaita, P. Pohjanjousi, T. Ikonen, E.S. Antonarakis, N. Cook
Journal: Annals of Oncology (2022)
1708P SMARCA4/SMARCB1 alterations detected through tissue comprehensive genomic profiling (CGP): A single-center study of prevalence and clinical characteristics
Authors: J. Bartolomé Arcilla, G. Fernandez-Hinojal, A. Manzano Fernández, M. Paz Cabezas, A. Ocana Fernandez, P. Pérez Segura
Journal: Annals of Oncology (2022)
1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
Authors: C.G. Porta, M. Eto, R.J. Motzer, U.F.F. De Giorgi, T. Buchler, N.S. Basappa, M.J. Mendez Vidal, S. Tjulandin, S.H. Park, B. Melichar, T.E. Hutson, C. Alemany, B. McGregor, C.S. He, R. Perini, K. Mody, J. McKenzie, T.K. Choueiri
Journal: Annals of Oncology (2022)
441TiP A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer
Authors: K. Ding, Y. Liu, Y. Song, D. Xu, J. Li, J. Wang, X. Chen, R. Lin, Y. Jiang, Y. Zhang, W. Zhang, Y. Cheng, X. Wu, Y. Yuan
Journal: Annals of Oncology (2022)
1699P Real-life molecular testing in lung cancer patients in a French non-academic public hospitals network: Results of a cohort of 9,000 lung cancer patients
Authors: A. Cortot, S. Couraud, O. Molinier, P. Slaouti, C. Delmas, E. Maetz, O. Leleu, P. Kuntz, S. Loutski Vettese, V. Levrat, H. Rabut, J-M. Dot, J-P. Kraemer, S. Larive, J.M. Peloni, F. El Khanjari, J. Obert, P. Beynel, A. Letierce, D. Debieuvre
Journal: Annals of Oncology (2022)
1198TiP A phase Ib/II open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer
Authors: J. Rodon, B. O’Neil, V. Wacheck, M. Liu, L.S. Rosen
Journal: Annals of Oncology (2022)
1659TiP A Spanish observational study for MOLecular characterization of THYroid carcinoma: MOLTHY Project – TTCC-2020-02
Authors: N. Baste Rotllan, J. Martinez Trufero, C. Alvarez Escola, T. Alonso Gordoa, E. Gallardo Diaz, J. Rubió-Casadevall, C.M. Vila, M. Plana Serrahima, A.J. Cunquero Tomas, C. Lopez Lopez, A.A. Segura Huerta, J. Hernando Cubero, M. Durán, C. Teixido, E.M. Ortega Izquierdo, R.M. Regojo, I. Ruz-Caracuel, T. Bonfill Abella, J.J. Grau, R. Mesia Nin
Journal: Annals of Oncology (2022)
270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort
Authors: L. Cucciniello, E. Blondeaux, C. Bighin, M.S. Gasparro, S. Russo, A. Dri, P. Pugliese, A. Fontana, G. Naso, A. Ferzi, F. Riccardi, V. Sini, A. Fabi, F. Montemurro, M. De Laurentiis, G. Arpino, L. Del Mastro, L. Gerratana, F. Puglisi
Journal: Annals of Oncology (2022)
1694P Single cell characterization of longitudinal biopsies from breast cancer patients treated with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib
Authors: X. Tekpli, S. Ghannoum, C.B. Steen, M. Fongård, B.C. Holm, T. Bosnjak, L.C. Reitsma, S.B. Geisler, M. Seyedzadeh, U-C. Buvarp, M. Loeng, M. Lyngra, V. Kristensen, J. Geisler
Journal: Annals of Oncology (2022)
1584P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) in a real-world analysis: A risk prediction nomogram
Authors: A. Ferro, F. Girardi, G. Pretelli, C. Mulargiu, M.V. Resi, B. Benetti, G.M. Marinato, M. Lorenzi, A. Dal Maso, S. Frega, G. Pasello, V. Guarneri, L. Bonanno
Journal: Annals of Oncology (2022)
1602P Causes of unplanned hospitalizations and factors associated with in-hospital mortality among patients receiving chemotherapy treatment
Authors: C.M.T. Hidalgo Filho, F. Lazar Neto, J.W.D. Rocha, V.P. Sobottka, L.T.B. Stangler, G. Benfatti, H. Guedes, M.Z. Claro, R.C. Bonadio, M.D.P.E. Diz, P.M. Hoff
Journal: Annals of Oncology (2022)
1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment
Authors: M.S. Brose, J.A. Krajewska, F. Vaisman, A.O. Hoff, E. Hitre, J. Oliver, D.S. Williamson, N. Berry, J. Capdevila Castillon
Journal: Annals of Oncology (2022)
1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial
Authors: A.J. Armstrong, O. Sartor, F. Saad, J. Czernin, N.D. Shore, A.T. Kendi, T.M. Beer, N. Vaishampayan, G. El-Haddad, J. Wu, O. Mirante, M.J. Morris
Journal: Annals of Oncology (2022)
1512P Pain in patients with desmoid fibromatosis (DF)
Authors: N. Penel, S. Bonvalot, A-M. Bimbai, A. Italiano, D. Orbach, B. Verret, M. Toulmonde, A. Dufresne, J-O. Bay, L. Chaigneau, J.E. Kurtz, E. Bompas, S. Salas, F. Bertucci, C. Guillemet, T. Ryckewaert, J. Thery, M-C. Le Deley, J-Y. Blay, A. Le Cesne
Journal: Annals of Oncology (2022)
1517P Role of geriatric assessment and oncological multidimensional prognostic index (onco-MPI) in older patients (age ≥70 years) with advanced soft tissue sarcoma in a real-world setting
Authors: B. Chiusole, I. Tortorelli, A. Galiano, F. Murtas, S. Ahcene Djaballah, G. Tierno, A. Banzato, M. Gatti, A. Di Maggio, G. Sergi, M. Rastrelli, M. Sbaraglia, V. Zagonel, A. Brunello
Journal: Annals of Oncology (2022)
1491MO New benchmarks for designing clinical trials in advanced or metastatic liposarcoma (LPS) or synovial sarcoma (SS): An EORTC soft tissue and bone sarcoma group meta-analysis
Authors: G. Kantidakis, S. Litiere, A. Neven, M. Vinches, I. Judson, J-Y. Blay, E. Wardelmann, S. Stacchiotti, L. D'Ambrosio, S.I. Marreaud, W.T.A. van der Graaf, B. Kasper, M. Fiocco, H. Gelderblom
Journal: Annals of Oncology (2022)
1369P Biochemical outcomes from ARTO trial (NCT03449719) a phase II randomized trial testing association between abiraterone acetate and stereotactic body radiation therapy in castrate-resistant prostate cancer patients
Authors: G. Francolini, B. Detti, V. Di Cataldo, S. Caini, A.R. Alitto, None S. Parisi, C. Demofonti, A. Bruni, G. Ingrosso, G. Timon, A.G. Allegra, L. Burchini, V. Salvestrini, G. Frosini, C. Cerbai, L. Visani, C. Becherini, I. Desideri, I. Meattini, L. Livi
Journal: Annals of Oncology (2022)
445TiP VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state
Authors: A. Pastorino, A. Puccini, V. Martelli, M. Grassi, M. Cremante, A. Gandini, S. Puglisi, F. Catalano, V. Murianni, A. Pessino, V. Andretta, S. Mammoliti, M.S. Sciallero, D. Comandini, G. Fornarini, F. Caprioni, G. Bregni, S. Barni, R. Labianca, A.F. Sobrero
Journal: Annals of Oncology (2022)
1759P Enfortumab vedotin in metastatic urothelial carcinoma: Retrospective multicentre patient cohort
Authors: C. Darr, S. Zschäbitz, G. Niegisch, F. Roghmann, P. Ivanyi, F. Zengerling, P. Paffenholz, N. Biernath, M. Klee, N. Klümper, R.L. Tauber, B.A. Hadaschik, T. Hilser, V. Grünwald
Journal: Annals of Oncology (2022)
1442P Prevalence and factors associated with professional burnout in Polish oncologists: A nationwide survey by Young Oncologists Section of Polish Society of Clinical Oncology
Authors: P. Sobczuk, A. Gawlik-Urban, D.S. Sigorski, A. Brodziak, J. Kiszka, M.N. Osmola, K.E. Machulska-Ciuraj, M. Wilk
Journal: Annals of Oncology (2022)
1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany
Authors: G. Mouillet, J. Bedke, L. Albiges, P. Barthelemy, B. Escudier, V. Gruenwald, P. Ivanyi, H. Mueller-Huesmann, Y-A. Vano, E. von der Heyde, F. Ejzykowicz, F. Brellier, M. Herber, C. Quentric, B.M. Bennett, S. Nere, A. Autengruber, A. Thiery-Vuillemin, M-O. Grimm
Journal: Annals of Oncology (2022)
1741P Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial
Authors: G.A. De Velasco Oria, I. García-Carbonero, E. Esteban-Gonzalez, A. Pinto, D. Lorente, A. Gómez de Liaño, E. Martínez Ortega, L. Jimenez Colomo, J. Puente, I. Gonzalez, O. Fernández, G. Anguera
Journal: Annals of Oncology (2022)
1516P Diagnostic delay due to COVID-19 pandemic in sarcoma patients: Single-centre retrospective SarCorD study (COMETA Project)
Authors: A. Cosimati, C.E. Onesti, S. Vari, F. Nardozza, G. Maggi, D. Minghelli, B. Rossi, F. Sperati, E. Checcucci, W. Faltyn, M.C. Cercato, F. Salvatori, F. Riva, R. Biagini, G. Ciliberto, V. Ferraresi
Journal: Annals of Oncology (2022)
1770P Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)
Authors: C.F. Stockem, A. Gil Jimenez, J. van Dorp, N. van Dijk, M. Alkemade, I. Seignette, C. Pipinikas, G. Jones, N. Rosenfeld, M.L. van Montfoort, K. Hendricksen, J. de Feijter, R. Meijer, A. van der Heijden, N. Mehra, B.B. Suelmann, B.W.G. van Rhijn, M.S. van der Heijden
Journal: Annals of Oncology (2022)
615TiP NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP–bevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery
Authors: G. Freyer, A.J. Gonzalez Martin, F. Raspagliesi, J. Peron, E. Van Nieuwenhuysen, K. Hasegawa, M-C. Lim, I.L. Ray-Coquard
Journal: Annals of Oncology (2022)
1432P Incorporating psycho-social factors in cancer treatment adverse events studies
Authors: C. Casini, D. Monzani, M. Masiero, K. Mazzocco, R. Grasso, D. Fotiadis, N. Memos, K. Keramida, G. Curigliano, C. Cipolla, D. Cardinale, A. Papakonstantinou, A. Constantinidou, C. Conti, G. Pravettoni
Journal: Annals of Oncology (2022)